Thus, high-profile studies investigating feasibility of the modality in terms of adverse effects seem premature.doi:10.1038/nrurol.2012.133GuillonneauBertrandNature Reviews UrologyGuillonneau B. Prostate cancer: New treatments for localized tumours—what matters first? Nat Rev Urol. 2012; 9 :414–5....
In the realm of medical advancements, the treatment of prostate cancer, a significant health concern for middle-aged men, has seen remarkable progress. This article, tailored for students from elementary to high school, aims to educate you on the basics of prostate cancer, new therapies, and ho...
Hormone therapy does not destroy cancer but research has shown effectiveness in enhancing other treatments. Hormone Therapy Side Effects May cause impotence, weight gain, hot flashes, fatigue, loss of muscle mass; and hormone “flare” in LHRH use. ...
In other words, while the new treatment for prostate cancer seems promising, more research is necessary to determine if it is as safe and effective as existing treatments. There is simply not enough scientific research available to guide us. In the meantime, industry is pushing a new and unpro...
New treatments for localized tumours—what matters first?doi:10.1038/nrurol.2012.133B. GuillonneauNature Reviews Urology
Prostate cancer affects one in every eight men during their lifetime, making it the most prevalent form of cancer for males. For many, the standard of care means facing aggressive treatments that include radiation and the freezing or removal of the entir
New method examines the genetic background of tumors for more effective prostate cancer therapy. Different approaches for deciphering genetic data could result in new prostate cancer treatments, a recent study suggests. Research has been increasingly driven towards personalized medicine or therapies that ...
Prostate cancer is the most commonly diagnosed malignancy and second leading cause of cancer-related deaths among men in the U.S. The challenge with prostate cancer is that the standard treatment methods in the advanced stage of the disease lose effectiv
Dr. Stephen Scionti is the most experienced HIFU physician in the U.S. using the alternative prostate cancer treatment for customized treatment.
LHRH agonists have also been used prior to or following various local treatments in patients with clinically localised prostate cancer and at high risk for disease recurrence [5]. Thus indications for the treatment with LHRH agonists include, besides T3 metastatic prostate cancer, patients with rising...